Crescent Biopharma Reports Zero Revenue, $20.1M Net Loss Amid Pipeline Development
Ticker: CBIO · Form: 10-Q · Filed: Jul 31, 2025 · CIK: 1253689
| Field | Detail |
|---|---|
| Company | Crescent Biopharma, INC. (CBIO) |
| Form Type | 10-Q |
| Filed Date | Jul 31, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Biotechnology, Pre-revenue, Net Loss, Clinical Trials, Cash Burn, SEC Filing, 10-Q
Related Tickers: CBIO
TL;DR
**CBIO is burning cash with no revenue, making it a high-risk bet on future pipeline success.**
AI Summary
CRESCENT BIOPHARMA, INC. (CBIO) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company incurred a net loss of $10.5 million for the three months ended June 30, 2025, and a net loss of $20.1 million for the six months ended June 30, 2025. A significant business change was the reverse recapitalization of GlycoMimetics Inc. on July 11, 2003, which is now reflected in the financial statements. Key risks include the company's dependence on successful clinical development and regulatory approval of its product candidates, as well as its need for substantial additional funding to continue operations. The strategic outlook focuses on advancing its pipeline, with a continued emphasis on research and development, as evidenced by ongoing expenditures in this area. The company's financial position shows total assets of $15.2 million as of June 30, 2025, down from $25.7 million as of December 31, 2024, indicating a significant burn rate.
Why It Matters
For investors, CBIO's lack of revenue and substantial net losses highlight the high-risk, high-reward nature of early-stage biopharma investments. The company's ability to secure future funding will be critical for its survival and competitive positioning against larger, more established pharmaceutical companies. Employees face job security risks if funding is not obtained, while customers are still years away from potentially benefiting from any approved therapies. The broader market will watch CBIO as a bellwether for the challenges faced by pre-commercial biotech firms in a tight capital environment.
Risk Assessment
Risk Level: high — The risk level is high due to CRESCENT BIOPHARMA's pre-revenue stage, reporting $0 revenue for both the three and six months ended June 30, 2025. The company also reported significant net losses of $10.5 million for the quarter and $20.1 million for the six-month period, indicating a substantial cash burn without any commercial products.
Analyst Insight
Investors should approach CBIO with extreme caution, recognizing it as a speculative investment. Monitor closely for news on clinical trial progress and, more importantly, any announcements regarding new financing rounds, as the company's current cash position and burn rate suggest a need for additional capital soon.
Key Numbers
- $0 — Revenue (for the three and six months ended June 30, 2025, indicating pre-commercial stage)
- $10.5M — Net Loss (for the three months ended June 30, 2025, reflecting ongoing R&D expenses)
- $20.1M — Net Loss (for the six months ended June 30, 2025, demonstrating significant cash burn)
- $15.2M — Total Assets (as of June 30, 2025, a decrease from $25.7M at December 31, 2024)
- $25.7M — Total Assets (as of December 31, 2024, showing a decline in financial resources)
- 2003-07-11 — Date of Name Change (when GlycoMimetics Inc. became CRESCENT BIOPHARMA, INC. via reverse recapitalization)
Key Players & Entities
- CRESCENT BIOPHARMA, INC. (company) — filer of the 10-Q
- GlycoMimetics Inc. (company) — former company name, subject of reverse recapitalization
- $10.5 million (dollar_amount) — net loss for the three months ended June 30, 2025
- $20.1 million (dollar_amount) — net loss for the six months ended June 30, 2025
- June 30, 2025 (date) — end of the reporting period for the 10-Q
- December 31, 2024 (date) — previous fiscal year-end for comparison of assets
- $15.2 million (dollar_amount) — total assets as of June 30, 2025
- $25.7 million (dollar_amount) — total assets as of December 31, 2024
- Waltham, MA (location) — business address of CRESCENT BIOPHARMA, INC.
- SEC (regulator) — regulator of 10-Q filings
FAQ
What were CRESCENT BIOPHARMA's revenues for the second quarter of 2025?
CRESCENT BIOPHARMA, INC. reported $0 in revenue for the three months ended June 30, 2025, consistent with its status as a pre-commercial stage biopharmaceutical company.
What was CRESCENT BIOPHARMA's net loss for the first half of 2025?
For the six months ended June 30, 2025, CRESCENT BIOPHARMA, INC. incurred a net loss of $20.1 million, reflecting significant research and development expenditures.
How have CRESCENT BIOPHARMA's total assets changed since the end of 2024?
CRESCENT BIOPHARMA's total assets decreased from $25.7 million as of December 31, 2024, to $15.2 million as of June 30, 2025, indicating a substantial reduction in its financial resources.
What is the primary business focus of CRESCENT BIOPHARMA, INC.?
CRESCENT BIOPHARMA, INC. is focused on the development of biopharmaceutical product candidates, currently operating in a pre-commercial stage with ongoing research and development activities.
What significant corporate event is mentioned in CRESCENT BIOPHARMA's 10-Q filing?
The 10-Q filing mentions a reverse recapitalization of GlycoMimetics Inc. on July 11, 2003, which resulted in the company now known as CRESCENT BIOPHARMA, INC.
What are the key risks for investors in CRESCENT BIOPHARMA?
Key risks for investors include the company's lack of revenue, significant net losses of $20.1 million for H1 2025, and the need for substantial additional funding to advance its product pipeline and continue operations.
Does CRESCENT BIOPHARMA have any commercial products currently generating revenue?
No, CRESCENT BIOPHARMA, INC. does not currently have any commercial products generating revenue, as evidenced by $0 revenue reported for the three and six months ended June 30, 2025.
What is the current cash burn rate for CRESCENT BIOPHARMA?
While not explicitly stated as a 'burn rate' percentage, the net loss of $20.1 million for the first six months of 2025 indicates a significant cash outflow, averaging over $3.3 million per month.
Where is CRESCENT BIOPHARMA, INC. headquartered?
CRESCENT BIOPHARMA, INC. is headquartered at 300 Fifth Avenue, Waltham, MA 02451, according to its business address in the filing.
What is the significance of the 'reverse recapitalization' for CRESCENT BIOPHARMA?
The reverse recapitalization of GlycoMimetics Inc. on July 11, 2003, is significant as it represents the foundational corporate restructuring that led to the current entity, CRESCENT BIOPHARMA, INC., and impacts the historical financial presentation.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on July 31, 2025 regarding CRESCENT BIOPHARMA, INC. (CBIO).